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Abstract 
The current professional interest brief aims to outline the feasibility of using the Implicit 
Relational Assessment Procedure (IRAP) in a pilot study of individuals who heard voices and 
of whom the majority had been given a diagnosis of psychosis, and a comparison sample of 
non-voice hearing controls against which the clinical data could be compared (clinical voice 
hearers, N=9; controls, N=9). The IRAP assessed acceptance and avoidance of positively 
versus negatively valenced voices. All clinical participants completed the IRAP in terms of 
reaching the standard accuracy and latency criteria, thus demonstrating that a clinical 
(specifically psychosis) sample can complete content-specific IRAPs. Indeed, some 
procedural modifications were required and these have been outlined in the current 
manuscript. Preliminary results at both the group and individual levels appear to be in a 
meaningful direction for the psychosis sample, but not for the controls, which was consistent 
with our predictions. Our preliminary data support the view that the IRAP may be used 
effectively with a resident in-patient population. 
 
Keywords: Clinical participants, psychosis, hearing voices, Implicit Relational Assessment 
Procedure (IRAP) 
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Novelty and Significance 
What is already known about the topic? 
 The IRAP is a useful tool for investigating clinical phenomena. 
 However, some populations have difficulty completing the IRAP, particularly those 
within an in-patient setting. 
What this paper adds. 
 The IRAP was successfully used within a medicated in-patient population with a 
diagnosis of psychosis. 
 Preliminary data appears to be in a meaningful direction.  
 Any necessary procedural modifications to the IRAP are outlined. 
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The purpose of this professional interest brief was to investigate the feasibility of using the 
Implicit Relational Assessment Procedure (IRAP) with a clinical sample who heard voices 
and most of whom had received a diagnosis of psychosis. Derived from Relational Frame 
Theory (RFT), the IRAP is a methodology used to directly assess the strength of target verbal 
relations (Barnes-Holmes, Hayden, Barnes-Holmes, & Stewart, 2008; Hussey, Barnes-
Holmes, & Barnes-Holmes, 2015). The procedure has shown robust effects in the study of 
many clinical phenomena (see Vahey, Nicholson, & Barnes-Holmes, 2015, for a recent meta-
analysis). Despite this body of work, researchers have sometimes queried the feasibility of 
using the IRAP in clinical populations, specifically among those who are currently taking 
high doses of psychotropic medication. The administration of the IRAP is possible within 
clinical populations, but additional procedures are often implemented to ensure that 
participants meet the IRAP’s practice block criteria of highly accurate responding within a 
brief response latency. The purpose of the current professional interest brief is to highlight 
additional procedures that are typically required, while presenting some preliminary data in 
this domain. 
One particularly challenging clinical group, in terms of conducting experimental 
psychological research, would be those with a diagnosis of psychosis, because they are 
typically heavily medicated and present with experiences that might interfere with 
completion of experimental tasks. Perhaps for this reason, only one published paper has 
reported the use of the IRAP with a group reporting experiences that are typically associated 
with a diagnosis of psychosis, voice-hearing (McEnteggart, Barnes-Holmes, Egger, & 
Barnes-Holmes, 2016). In three studies, non-clinical voice hearers and controls were 
compared using IRAPs that assessed responses to voice hearing. The IRAP successfully 
predicted aspects of voice hearing and psychological well-being, but of course, all 
participants were non-clinical, and thus the relevance of this finding does not address directly 
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the concerns sometimes raised by other researchers about the utility of the IRAP in the 
clinical domain. 
In the current paper, we report the method we used and the data obtained from a 
clinical sample of voice hearers with the IRAP. Specifically, we used an Acceptance-
Avoidance IRAP which contrasted avoidance and acceptance of positively and negatively 
valenced voices. The data we report were gathered with a small N and are used simply to 
demonstrate the feasibility of using the IRAP with a clinical sample who might be seen as a 
particularly challenging group. The data are compared, however, with a small control sample 
to determine if the general effects observed differ in a meaningful way between the clinical 
and non-clinical samples. 
Method 
Participants 
The current study involved two groups of participants. One group was categorized as 
clinical voice hearers and the other comprised a non-voice hearing control group. Originally, 
14 clinical voice hearers were recruited from a psychiatric facility, eight of these were male 
and six were female. Five of these participants were excluded from the study because they 
did not meet performance criteria on the IRAP. Therefore, nine clinical voice hearers 
successfully completed the study, five of these were male and four were female. Five out of 
the nine clinical voice hearers had an independent diagnosis of schizophrenia, while the 
remaining four had a diagnosis of: schizoaffective disorder, psychotic disorder (not otherwise 
specified), personality disorder, and substance dependence. All were taking psychotropic 
medication. Four participants were also diagnosed with comorbid substance dependence and 
substance abuse, and these participants were asked to abstain from drugs and alcohol prior to 
participation. All nine participants were administered stable doses of medication during the 
period of participation. 
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Twelve non-voice hearers were recruited initially, five were male and seven were 
female. All were identified from the same general sample of undergraduate students, and self-
reported that they had no previous contact with mental health services. Three of these 
participants were excluded from the study because they did not meet performance criteria on 
the IRAP. Therefore, nine non-voice hearers successfully completed the study, four of these 
were male and five were female. 
Settings 
The current study was conducted in two locations. The non-voice hearing controls 
participated in an experimental cubicle in a university. The clinical voice hearers participated 
in a research room in a psychiatric facility. All participation was on an individual basis. For 
the non-voice hearers, the experimenter interacted with participants only during instructional 
phases of the IRAP, and remained seated behind participants at all other times. On average, 
these sessions lasted between 30 and 60 minutes and, all participation was completed in one 
session. For the clinical voice hearers, it was necessary for the experimenter to interact with 
participants during all phases of the experiment. Participants were offered multiple 
opportunities to take breaks between the blocks of the IRAP, which significantly extended the 
duration of the experiment. On average, these sessions lasted between 1.5 and 4 hours (with 
regular breaks as requested) and all participation was completed in two to eight sessions. 
Materials 
The IRAP. The IRAP is a computerized procedure that presents stimuli and 
instructions, and records responses. The current study involved an Acceptance-Avoidance 
IRAP that assessed the avoidance and acceptance of voices. The Acceptance-Avoidance 
IRAP contrasted positive and negative voices, using the labels “If my voices are pleasant” 
and “If my voices are annoying”. Each trial-type presented one of these two category labels, 
accompanied by one of six avoidance-based (e.g., “I block them out”) or six acceptance-
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based target stimuli (e.g., “I cherish them”), with “True” and “False” as response options. 
The Acceptance-Avoidance IRAP produced four trial-types: pleasant-accept; pleasant-avoid; 
annoying-accept; and annoying-avoid.  
During blocks of trials that were deemed consistent with historical verbal relations for 
the clinical sample, the following responses were correct: Pleasant Voices-Accept/True; 
Pleasant Voices-Avoid/False; Annoying Voices-Accept/False; Annoying Voices-Avoid/True. 
During blocks of trials that were inconsistent with natural verbal relations, the following 
responses were correct: Pleasant Voices-Accept/False; Pleasant Voices-Avoid/True; 
Annoying Voices-Accept/True; Annoying Voices-Avoid/False. Defining relations as 
consistent or inconsistent for the control sample was difficult because they do not hear 
voices, but for the purpose of analysis, the IRAP relations are defined in the same way as for 
the clinical sample. A full list of label stimuli, target stimuli, and response options for the 
IRAP is provided in Table 1. 
INSERT TABLE 1 HERE 
In the interest of transparency, the current study employed a number of self-report 
measures, however due to the scope of the current professional interest brief, those data will 
not be presented. These measures comprised of: the Community Assessment of Psychic 
Experience (CAPE; Stefanis et al., 2002); the Auditory Hallucinations Ratings Scale (AHRS; 
Haddock, McCarron, Tarrier, & Farragher, 1999); the Beliefs About Voices Questionnaire-
Revised (BAVQ-R; Chadwick, Lees, & Birchwood, 2000); the Voices Acceptance and 
Action Questionnaire (VAAS; Shawyer et al., 2007); the Acceptance and Action 
Questionnaire II (AAQ-II; Bond et al., 2011); and the Depression Anxiety and Stress Scales 
(DASS-21; Lovibond & Lovibond, 1995). 
Procedure 
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Prior to commencing the experiment, participants were informed about the broad aims 
of the research and advised that at any time during the experiment they were free to 
discontinue participation. Confidentiality and anonymity were assured, and informed consent 
was obtained both through an informed consent form and via the IRAP program. The 
experimental session began once it was clear that all participants understood what was 
required of them. 
Identification of non-voice hearers. All control participants were instructed that the 
experience of hearing voices was the focus of the study. However, in order to ensure that the 
study was accurately measuring appraisals to voice hearing as “auditory verbal 
hallucinations” and no other phenomena, all non-clinical participants were provided with a 
written explanation of voice hearing, and instructed that this was the focus of the study. 
Participants were then identified as non-voice hearing controls using the CAPE measure. 
Specifically, if participants indicated that they did not hear voices, they were allocated to the 
non-voice hearing group. If participants indicated that they did hear voices, their participation 
ended, and they were thanked and debriefed.   
IRAP. Prior to the first practice block, participants were verbally instructed on how to 
complete an IRAP. That is, they were advised that each trial would present a phrase on top, 
with another phrase in the center, and that their task was to respond with “True” or “False”, 
as appropriate. Participants were informed that the pattern of responding would switch to an 
opposite pattern across each block. These instructions also highlighted the criterion for 
accurate (i.e., >80%) and fast (i.e., <2,000 ms.) responding. Some clinical participants found 
it difficult to remember which pattern of responding they were currently required to follow, 
so each participant was offered hardcopy post-it notes as a reminder of the two patterns (i.e., 
pro-pleasant voices/anti-annoying voices, and anti-pleasant voices/pro-annoying voices). 
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The IRAP consisted of blocks of 24 trials, with each of the four trial-types presented 
six times within each block. On each trial, a label (e.g., “If my voices are pleasant”) appeared 
at the top, a target (e.g., “I accept them”) in the middle, and both response options (“True” 
and “False”) on the bottom left- and right-hand corners. Participants selected a response by 
pressing D (for the left option) or K (for the right). If a participant emitted a correct response, 
the screen cleared, and the next trial appeared. If a participant responded incorrectly, a red X 
appeared until a correct response was emitted.  
The feedback contingencies for the IRAP alternated across blocks in one of two 
patterns. One pattern was defined as accept-pleasant/avoid-annoying voices, the other as 
accept-annoying/avoid-pleasant voices. The accept-pleasant/avoid-annoying voices pattern 
required that participants respond in the following way: Pleasant Voices-Accept/True; 
Pleasant Voices-Avoid/False; Annoying Voices-Accept/False; Annoying Voices-Avoid/True. 
The accept-annoying/avoid-pleasant voices pattern required the opposite: Pleasant Voices-
Accept/False; Pleasant Voices-Avoid/True; Annoying Voices-Accept/True; Annoying 
Voices-Avoid/False. Hence, correct responding involved switching between each pattern 
from block to block. The order in which the two types of blocks were presented was 
counterbalanced across participants. 
The IRAP commenced with a minimum of two practice blocks. If participants failed 
to achieve both accuracy and latency criteria across a pair of blocks, they received automated 
feedback, and practice blocks continued to a maximum of four pairs of blocks. Failing to 
meet the criteria after four pairs of practice blocks terminated participation and these data 
were discarded. When the criteria were reached on a pair of practice blocks, participants 
proceeded automatically to three pairs of test blocks. No performance criteria were employed 
for participants to progress through test blocks, but performance feedback was presented at 
the end of each block to encourage participants to maintain the criteria. The program 
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automatically recorded response accuracy (based on the first response emitted on each trial) 
and response latency (time in milliseconds between trial onset and emission of correct 
response) on each trial. Once participants finished the IRAP, they completed the six explicit 
measures in a pre-determined sequence (AHRS, BAVQ-R, VAAS, CAPE, AAQ-II, and 
DASS), but as noted above, the data from these will not be presented here. 
Procedural Modifications for the Clinical Sample 
While the majority of clinical voice hearers employed in the current study 
successfully completed the IRAP, the long-term use of medication (which is often 
characteristic of this population) may influence participants’ ability to complete the task 
within the IRAP’s criteria. To circumvent these issues, a number of additional procedural 
measures were implemented to facilitate the successful completion of the task. It should be 
noted, however, that not all participants required these additional measures – a functional 
assessment of the participant’s requirements was carried out on a participant-by-participant 
basis by an experienced researcher, and some of the following procedural modifications were 
made where necessary.  
1. Due to the potential effects of medication on fatigue and motivation, the 
researcher aimed to schedule the experiment during the participants’ optimum 
medication window. To do this, the researcher consulted with participants about 
their weekly schedule and then discussed the best time of day that they might like 
to complete the study.  
2. All clinical participants were subjected to an initial exposure of the IRAP one 
week prior to the actual exposure. The initial exposure presented all aspects of 
the IRAP task (i.e., the practice and test blocks) to familiarize participants with all 
aspects of the task and to provide participants with an opportunity to ask 
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questions. If participants met the IRAP criteria during the initial exposure, they 
were not required to complete the actual exposure one week later.  
3. Given the sensitivity of the content of the IRAP stimuli, participants were assured 
that the IRAP was not designed to change their current beliefs about, or the way 
in which they respond to, their voices. Participants were simply informed during 
the debriefing session that the IRAP was designed to assess which pattern of 
responding they find easier, if any.  
4. During any stages of the practice or test sessions, if participants appeared to be 
fatigued, they were offered an opportunity to take a break between the practice 
and test blocks of the IRAP. This significantly extended the duration of the 
experiment.  
5. In the instance where participants found it difficult to remember which block of 
trials they were currently on, they were permitted to make Post-it notes of the two 
block patterns and alternate these on their screen between blocks. 
6. Given the potential susceptibility of this sample toward paranoid experiences, 
participants were assured of the safety, anonymity, and confidentiality of their 
data, including who has access and where it will be stored. Participants were also 
assured that their data would not be used for diagnostic purposes, nor would it be 
analyzed on a single-subject basis.  
Results 
IRAP Data 
Scoring of the IRAP was conducted using the standardized approach for transforming 
latency data into DIRAP scores for each participant as outlined for previous IRAP studies (see 
Nicholson & Barnes-Holmes, 2012a). The foregoing data transformation yields positive 
DIRAP scores for acceptance of voices and negative DIRAP scores for avoidance of voices. All 
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data from any non-voice hearing participant that fell below 80% accuracy and was above a 
2000ms latency on any of the six test blocks were omitted from the dataset. However, if 
clinical participants fell below 80% accuracy and were above a 2000ms latency during the 
test blocks of the IRAP, their data were still included in the analyses if they remained above 
75% accuracy and below 2500ms on each of the three test block pairs. Although somewhat 
arbitrary, adopting slightly relaxed criteria with this population is deemed acceptable, given 
that previous studies have reported slower reaction times in this sample on implicit and other 
measures (Wiffen et al., 2013).  
Between groups data. The mean DIRAP scores for the two groups on the Acceptance-
Avoidance IRAP are presented in Figure 1. On Pleasant-Accept, the clinical voice hearers 
showed greater acceptance of positive voices than controls. On Pleasant-Avoid, both groups 
showed marginal acceptance of positive voices. On Annoying-Accept, the control group 
showed acceptance, whereas the clinical voice hearers showed almost no effect, that is, they 
did not confirm that annoying voices should be accepted any more quickly than denying this. 
On Annoying-Avoid, both groups showed avoidance, with the clinical group showing the 
smaller effect. Eight one-sample t-tests were conducted to investigate whether any of the 
observed effects were significantly different from zero, but only the Pleasant-Accept trial-
type was significant for the clinical group (df = 8, t = 2.268, p < 0.05). 
INSERT FIGURE 1 HERE 
Clinical data from individual participants. The mean DIRAP scores for each of the 
nine participants on the Acceptance-Avoidance IRAP are presented in Figure 2. Upon 
inspection of these data, it can be seen that there is a clear pattern on the Pleasant-Accept 
trial-type, in which eight out of nine participants (except P8) responded in a manner that 
showed acceptance of pleasant voices. A one-sample Wilcoxon Signed-ranks test indicated 
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that the probability of acceptance of pleasant voices was significant for clinical participants 
(p < 0.05). 
INSERT FIGURE 2 HERE 
Control data from individual participants. The mean DIRAP scores for each of the 
nine participants on the Acceptance-Avoidance IRAP are presented in Figure 3. Unlike the 
clinical data, there is no clear pattern on any of the four trial-types. Four one-sample 
Wilcoxon Signed-ranks tests indicated that the probabilities of each of the four effects were 
not significant (all ps > 0.05). 
INSERT FIGURE 3 HERE 
Discussion 
The purpose of this professional interest brief was to investigate the feasibility of 
using the IRAP with a clinical sample who heard voices, had mostly received a diagnosis of 
psychosis, and were currently residing as in-patients. In doing so, we administered an 
Acceptance-Avoidance IRAP that contrasted avoidance and acceptance of positive and 
negative voices to a clinical sample of voice hearers and a non-voice hearing control group. 
Nine out of 14 clinical participants successfully completed the IRAP, and the preliminary 
IRAP effects recorded indeed appeared to separate out the clinical group from the control 
group on the Pleasant-Accept trial-type. Specifically, the probability of responding on this 
trial-type in a manner that is consistent with accepting pleasant voices was significant for the 
clinical group (8/9 cases). This difference was not found on any of the other trial-types.  
Although post-hoc, a possible explanation for the reason that clinical participants 
showed a bias towards accepting pleasant voices is that these individuals were currently in 
therapy that sought to undermine or reduce avoidance in the presence of negative and 
unwanted voices, with little or no focus on positive voices (based on the assumption that 
positive voices do not cause distress). In this respect, it is interesting that on the Annoying-
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Avoid trial-type, the clinical group did not confirm that annoying voices should be avoided 
(avoidance would be typical of this population, see Brett et al., 2007). In contrast, the control 
group of non-voice hearers showed no clear pattern on any trial-type, suggesting that voice 
hearing trial-types of the IRAP were, perhaps, not particularly meaningful for them. Overall, 
our preliminary data support the view that the IRAP may be used effectively with a resident 
in-patient population, who are currently medicated, undergoing therapy, and are typically 
seen as having a very severe clinical diagnosis. 
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Tables and Figures 
 
 
Figure 1. Mean DIRAP scores for the two groups on the Acceptance-Avoidance IRAP. Positive 
DIRAP scores indicate acceptance effects and negative DIRAP scores indicate avoidance effects. 
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Figure 2. Mean DIRAP scores for each of the nine clinical voice hearers on the Acceptance-
Avoidance IRAP. The four trial-types from left to right are: Pleasant-Accept, Pleasant-Avoid, 
Annoying-Accept, Annoying-Avoid. Positive scores indicate acceptance effects and negative 
DIRAP scores indicate avoidance effects. 
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Figure 3. Mean DIRAP scores for each of the nine non-voice hearers on the Acceptance-
Avoidance IRAP. The four trial-types from left to right are: Pleasant-Accept, Pleasant-Avoid, 
Annoying-Accept, Annoying-Avoid. Positive scores indicate acceptance effects and negative 
DIRAP scores indicate avoidance effects. 
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Table 1 
Stimuli and Response Options as presented in the Acceptance-Avoidance IRAP 
 
If my voices are pleasant I If my voices are annoying I 
Welcome them 
Try to keep them 
Accept them 
Listen to them 
Cherish them 
Am open to them 
Block them out 
Ignore them 
Suppress them 
Try to stop them 
Abstract myself 
Shut them up 
True/False 
 
 
 
 
